PT2277890E - Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma - Google Patents
Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma Download PDFInfo
- Publication number
- PT2277890E PT2277890E PT97506695T PT09750669T PT2277890E PT 2277890 E PT2277890 E PT 2277890E PT 97506695 T PT97506695 T PT 97506695T PT 09750669 T PT09750669 T PT 09750669T PT 2277890 E PT2277890 E PT 2277890E
- Authority
- PT
- Portugal
- Prior art keywords
- peptide
- interest
- plasma
- life
- extending half
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008136106 | 2008-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2277890E true PT2277890E (pt) | 2016-03-31 |
Family
ID=41340233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97506695T PT2277890E (pt) | 2008-05-23 | 2009-05-22 | Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma |
Country Status (16)
Country | Link |
---|---|
US (1) | US8551937B2 (pt) |
EP (1) | EP2277890B1 (pt) |
JP (1) | JP5524049B2 (pt) |
KR (2) | KR101350251B1 (pt) |
CN (1) | CN101809029B (pt) |
BR (1) | BRPI0904622A2 (pt) |
CA (1) | CA2698582C (pt) |
CY (1) | CY1117478T1 (pt) |
DK (1) | DK2277890T3 (pt) |
ES (1) | ES2566830T3 (pt) |
HR (1) | HRP20160303T1 (pt) |
HU (1) | HUE028539T2 (pt) |
PL (1) | PL2277890T3 (pt) |
PT (1) | PT2277890E (pt) |
SI (1) | SI2277890T1 (pt) |
WO (1) | WO2009142307A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1759001T3 (da) | 2004-04-21 | 2011-08-01 | Enobia Pharma Inc | Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen |
EP2432489B1 (en) * | 2009-05-20 | 2016-10-05 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
CN107261119A (zh) | 2011-02-28 | 2017-10-20 | 独立行政法人国立循环器病研究中心 | 恶性肿瘤转移抑制用药物 |
KR20140054084A (ko) * | 2011-08-19 | 2014-05-08 | 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 | 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약 |
JPWO2013099376A1 (ja) * | 2011-12-26 | 2015-04-30 | 国立大学法人福井大学 | 体外受精における成熟卵子マーカー及びその使用 |
KR20150013455A (ko) | 2012-04-25 | 2015-02-05 | 다이이찌 산쿄 가부시키가이샤 | 골 수복 촉진제 |
WO2013172967A1 (en) | 2012-05-17 | 2013-11-21 | Extend Biosciences, Inc | Carriers for improved drug delivery |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
TW201442721A (zh) | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
WO2015129812A1 (ja) * | 2014-02-27 | 2015-09-03 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc | 治療用ビタミンdコンジュゲート |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3226891A1 (en) | 2014-12-05 | 2017-10-11 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
EP3337894A1 (en) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
EP3964522A1 (en) * | 2015-11-16 | 2022-03-09 | Ubiprotein, Corp. | A method for extending half-life of a protein |
PL3400019T3 (pl) * | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
NZ743489A (en) * | 2016-01-08 | 2022-09-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
US20190218274A1 (en) * | 2016-05-06 | 2019-07-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
WO2018139464A1 (ja) | 2017-01-24 | 2018-08-02 | 第一三共株式会社 | 低身長症治療剤 |
WO2018175534A1 (en) * | 2017-03-22 | 2018-09-27 | Pharmain Corporation | Npra agonists, compositions, and uses thereof |
CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
EP4393502A2 (en) * | 2018-12-26 | 2024-07-03 | Skinmed Co., Ltd. | Acetylcholine receptor inhibitory peptides and uses thereof |
KR20220019785A (ko) | 2019-06-12 | 2022-02-17 | 노파르티스 아게 | 나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법 |
JP2024506912A (ja) | 2021-02-12 | 2024-02-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼポリペプチド及びその使用方法 |
US12233115B2 (en) | 2022-09-30 | 2025-02-25 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
WO2024162772A1 (ko) * | 2023-02-01 | 2024-08-08 | 주식회사 에이티지씨 | 생체 내 지속성이 증가된 생리활성물질의 결합체 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3026354B2 (ja) * | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
US20060263382A1 (en) * | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
IL147652A0 (en) | 1999-07-23 | 2002-08-14 | Kangawa Kenji | Novel peptides |
IL160289A0 (en) | 2001-08-30 | 2004-07-25 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
CN101519449A (zh) * | 2001-08-30 | 2009-09-02 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
RU2420306C2 (ru) * | 2005-11-21 | 2011-06-10 | Юниверсити Оф Миязаки | ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ДЛЯ УСКОРЕННОГО ЗАЖИВЛЕНИЯ КОЖИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ГРЕЛИН И ЕГО ПРОИЗВОДНЫЕ ИЛИ ВЕЩЕСТВО, ВОЗДЕЙСТВУЮЩЕЕ НА РЕЦЕПТОР GHS-R1a |
JPWO2007058360A1 (ja) * | 2005-11-21 | 2009-05-07 | 国立大学法人 宮崎大学 | デスアシルグレリン及びその誘導体を有効成分とする皮膚修復促進治療剤 |
CN101516399A (zh) * | 2006-08-11 | 2009-08-26 | 国立大学法人宫崎大学 | 以去酰基化的生长素释放肽及其衍生物作为有效成分的脊髓神经修复促进治疗剂 |
KR20090060291A (ko) | 2006-08-11 | 2009-06-11 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 그렐린 및 그 유도체 또는 GHS―R1a에 작용하는 물질을 유효성분으로 포함하는 척수 신경 수복 촉진 치료제 |
US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
-
2009
- 2009-05-22 JP JP2010513074A patent/JP5524049B2/ja not_active Expired - Fee Related
- 2009-05-22 PL PL09750669T patent/PL2277890T3/pl unknown
- 2009-05-22 HU HUE09750669A patent/HUE028539T2/en unknown
- 2009-05-22 KR KR1020107004795A patent/KR101350251B1/ko active IP Right Grant
- 2009-05-22 PT PT97506695T patent/PT2277890E/pt unknown
- 2009-05-22 CN CN200980100291.9A patent/CN101809029B/zh not_active Expired - Fee Related
- 2009-05-22 DK DK09750669.5T patent/DK2277890T3/en active
- 2009-05-22 ES ES09750669.5T patent/ES2566830T3/es active Active
- 2009-05-22 SI SI200931387T patent/SI2277890T1/sl unknown
- 2009-05-22 BR BRPI0904622A patent/BRPI0904622A2/pt not_active Application Discontinuation
- 2009-05-22 WO PCT/JP2009/059464 patent/WO2009142307A1/ja active Application Filing
- 2009-05-22 KR KR1020127034358A patent/KR20130018965A/ko not_active Application Discontinuation
- 2009-05-22 CA CA2698582A patent/CA2698582C/en not_active Expired - Fee Related
- 2009-05-22 US US12/675,961 patent/US8551937B2/en active Active
- 2009-05-22 EP EP09750669.5A patent/EP2277890B1/en active Active
-
2016
- 2016-03-22 CY CY20161100242T patent/CY1117478T1/el unknown
- 2016-03-23 HR HRP20160303TT patent/HRP20160303T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DK2277890T3 (en) | 2016-02-08 |
SI2277890T1 (sl) | 2016-04-29 |
CN101809029B (zh) | 2016-06-15 |
US20100305031A1 (en) | 2010-12-02 |
CA2698582A1 (en) | 2009-11-26 |
ES2566830T3 (es) | 2016-04-15 |
WO2009142307A1 (ja) | 2009-11-26 |
KR20130018965A (ko) | 2013-02-25 |
CY1117478T1 (el) | 2017-04-26 |
PL2277890T3 (pl) | 2016-06-30 |
HUE028539T2 (en) | 2016-12-28 |
EP2277890B1 (en) | 2016-01-06 |
EP2277890A4 (en) | 2011-08-24 |
JP5524049B2 (ja) | 2014-06-18 |
US8551937B2 (en) | 2013-10-08 |
CN101809029A (zh) | 2010-08-18 |
KR101350251B1 (ko) | 2014-01-14 |
KR20100038236A (ko) | 2010-04-13 |
EP2277890A1 (en) | 2011-01-26 |
JPWO2009142307A1 (ja) | 2011-09-29 |
HRP20160303T1 (hr) | 2016-04-22 |
BRPI0904622A2 (pt) | 2016-06-21 |
CA2698582C (en) | 2016-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2277890E (pt) | Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma | |
HK1250042A1 (zh) | 溶酶體靶向肽及其應用 | |
GB0914110D0 (en) | Peptide libraries | |
GB0913775D0 (en) | Multispecific peptides | |
EP2131390A4 (en) | PLASMA PROCESSOR | |
HK1214177A1 (zh) | 用於癌症的肽治療劑 | |
PL2421884T3 (pl) | Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje | |
IL216223A0 (en) | Methods of analyzing peptide mixtures | |
GB0920981D0 (en) | Peptides | |
GB2462761B (en) | Protein formulation | |
EP2373272A4 (en) | STALL ARTICLE | |
TWI319863B (en) | Plasma display | |
EP2270141A4 (en) | Lacritin PART PEPTIDE | |
HK1217912A1 (zh) | 控釋肽製劑 | |
EP2123666A4 (en) | PEPTIDE | |
IL216199A (en) | A peptide containing the sequence ednimvtfrnqasr | |
EP2478010A4 (en) | PART PEPTIDE OF LACRITINE | |
GB0724953D0 (en) | Methods of peptide modification | |
HK1151242A1 (en) | Mntf peptide compositions and methods of use mntf | |
ZA201203722B (en) | Peptide | |
EP2504065A4 (en) | STABLE MIXTURES AND RELATED METHODS | |
EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
EP2188305A4 (en) | MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS | |
GB0920987D0 (en) | Peptides | |
GB0817978D0 (en) | Peptides |